LS 301 IT
Alternative Names: LS-301-ITLatest Information Update: 12 Dec 2024
At a glance
- Originator Integro Theranostics
 - Class Imaging agents
 - Mechanism of Action Diagnostic imaging enhancers
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Phase I/II Breast cancer
 - Phase I Lung cancer
 - Preclinical Gynaecological cancer
 
Most Recent Events
- 11 Nov 2024 Phase-I clinical trials in Lung cancer (Diagnosis) in USA (IV) (NCT06713564)
 - 24 Jul 2023 Integro Theranostics plans a phase Ib/II trial for Breast cancer (Diagnosis, In adults, In the elderly) in USA (IV, Injection), in July 2023 (Integro Theranostics pipeline, July 2023) (NCT05900986)
 - 24 Jul 2023 Preclinical trials in Gynaecological cancer (Diagnosis) in USA (IV), prior to July 2023 (Integro Theranostics pipeline, July 2023)